Variations in the serum levels of soluble CD23, nitric oxide and IgE across the spectrum of American cutaneous leishmaniasis

Acta Tropica

Volumn 88, Issue 2, 2003, Pages 145-151

  Cabrera, Maira ^a   Rodriguez, Orquídea ^a   Monsalve, Iraima ^a   Tovar, Robert ^a   Hagel, Isabel ^a  

^a INSTITUTO DE BIOMEDICINA   (Venezuela)

Author keywords

CD23; Cutaneous leishmaniasis; IgE; Nitric oxide

Indexed keywords

CD23 ANTIGEN; IMMUNOGLOBULIN E; NITRATE; NITRIC OXIDE; NITRITE; PROTOZOON ANTIBODY;

LEISHMANIASIS; NITRIC OXIDE;

ADOLESCENT; ADULT; ANALYTIC METHOD; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIGEN DETECTION; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; CHRONIC DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; QUANTITATIVE ANALYSIS; RANK SUM TEST; SKIN LEISHMANIASIS; SOLUBILITY;

EID: 0141456078     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-706X(03)00198-0     Document Type: Article

References (30)

1. Afchain D., Desjeux P., La Fuente C., Le Ray D., Cesbron J.Y., Neyink J.L., Capron A. Specific IgE antibodies to Leishmania braziliensis in patients with mucocutaneous leishmaniasis. Ann. Immunol. (Paris). 134C:1983;311-319.
2. Armant M., Ishihara H., Rubio M., Delespesse G., Serfati M. Regulation of cytokine production by soluble CD23: coestimulation of interferon gamma secretion and triggering of tumor necrosis factor alpha release. J. Exp. Med. 180:1994;1005-1011.
3. Armant M., Rubio M., Delespesse G., Sarfati M. Soluble CD23 directly activates monocytes to contribute to the antigen-independent stimulation of resting T cells. J. Immunol. 155:1995;4868-4875.
4. Cabrera, M., 1994. T cell responses associated with immunotherapy of American cutaneous leishmaniasis. Ph.D. Thesis, University of London.
5. Cáceres-Dittmar G., Tapia F.J., Sanchez M., Yamamura M., Uyemura K., Modlin B.L., Bloom B.R., Convit J. Determination of the cytokine profile in American cutaneous leishmaniasis using the polymerase chain reaction. Clin. Exp. Immunol. 91:1993;500-505.
6. Castés M., Trujillo D., Rojas M.E., Fernandez C.T., Araya L., Cabrera M., Blackwell J., Convit J. Serum levels of tumor necrosis factor in patients with American cutaneous leishmaniasis. Biol. Res. 26:1993;233-238.
7. Castés M., Cabrera M., Trujillo D., Rodas A., Scott D., Blackwell J.M., Convit J. Cytokine profile in human American cutaneous leishmaniasis. New dimensions in parasitology. Acta Parasitol. Turc. Suppl. 1:1996;45-57.
8. Coffman R.L., Corty J. A T cell activity enhances polyclonal IgE production and its inhibition by interferon-gamma. J. Immunol. 136:1986;949.
9. Convit J. Leprosy and leishmaniasis. Similar clinical-immunological-pathological models. Ethiop. Med. J. 12:1974;187-195.
10. Convit J., Pinardi M.E., Rondon A. Diffuse cutaneous leishmaniasis: a disease due to an immunological defect of the host. Trans. R. Soc. Trop. Med. Hyg. 66:1972;603-610.
11. Convit J., Ulrich M., Fernandez C.T., Tapia F.J., Caceres-Dittmar G., Castes M., Rondon A.J. The clinical and immunological spectrum of American cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 87:1993;444-448.
12. Delespesse G., Suter U., Mossalayi D., Bettler B., Sarfati M., Hoftetter H., Kilcheir E., Debre P., Dallaul A. Expression, structure, and function of the CD23 antigen. Adv. Immunol. 49:1991;149-191.
13. Díaz N.L., Zerpa O., Ponce L.V., Convit J., Rondon A.J., Tapia F.J. Intermediate or chronic cutaneous leishmaniasis: leukocyte immunophenotypes and cytokines characterization of the lesion. Exp. Dermatol. 11:2002;34-41.
14. 15N ] nitrate in biological fluids Anal. Biochem. 126:1982;131-138.
15. Heinzel F.P., Sadick M.D., Holaday B.J., Coffman R.L., Locksley R.M. Reciprocal expression of interferon-γ or interleukin-4 during the resolution or progression of murine leishmaniasis. Evidence of distinct helper T cell subsets. J. Exp. Med. 169:1989;59-72.
16. Lynch N.R., Yarzabal L., Verde O., Avila J.L., Monzon H., Convit J. Delayed-type hypersensitivity and immunoglobulin E in American cutaneous leishmaniasis. Infect. Immun. 38:1982;877-881.
17. Melby P.C., Andrade-Narvaez F., Darnell B.J., Valencia-Pacheco G., Tryon V.V., Palomo-Cetina A. Increased expression of proinflammatory cytokines in chronic lesions of human cutaneous leishmaniasis. Infect. Immun. 62:1994;837-842.
18. Melby P.C., Andrade-Narvaez F., Darnell B.J., Valencia-Pacheco G. In situ expression of interleukin-10 and interleukin-12 in active human cutaneous leishmaniasis. FEMS Immunol. Med. Microbiol. 15:1996;101-107.
19. Moshage H., Kock B., Huizenga J.R., Jansen R.L. Nitrite and nitrate determinations in plasma: a critical evaluation. Clin. Chem. 41:1995;1025-1028.
20. Mossalayi M.D., Arock M., Debré P. CD23/FcεRII: signaling and clinical implication. Int. Rev. Immunol. 16:1997;129-146.
21. Nacher M., Gay F., Singhasivanon P., Krudsood S., Treeprasertsuk S., Mazier D., Vouldoukis I., Looareesuwan S. Ascaris lumbricoides infection is associated with protection from cerebral malaria. Parasite Immunol. 22:2000;107-113.
22. Nacher M., Gay F., Singhasivanon P., Kaewkungwal J., Silachamroon U., Treeprasertsuk S., Tosukhowong T., Vannaphan S., Looareesuwan S. Relationship between reactive nitrogen intermediates and total immunoglobulin E, soluble CD21 and soluble CD23: comparison between cerebral malaria and nonsevere malaria. Parasite Immunol. 24:2002;395-399.
23. O'Neil C.E., Labrada M., Saravia N.G. Leishmania (Viannia) panamensis-specific IgE and IgA antibodies in relation to expression of human tegumentary leishmaniasis. Am. J. Trop. Med. Hyg. 49:1993;181-188.
24. Paul-Eugene N., Mossayi D., Sarfati M., Yamaoka K., Aubry J.P., Bonnefoy J.Y., Dugas B., Kolb J.P. Evidence for a role of Fc epsilon RII/CD23 in the IL-4 induce nitric oxide production by normal human mononuclear phagocytes. Cell. Immunol. 163:1995;314-318.
25. Pirmez C., Cooper C., Paes-Oliveira M., Schubach A., Torigian V.K., Modlin R.L. Immunogenic responsiveness in American cutaneous leishmaniasis lesions. J. Immunol. 145:1990;3100-3104.
26. Pirmez C., Yamamura M., Uyemura K., Paes-Oliveira M., Modlin R.L. Cytokine patterns in the pathogenesis of human leishmaniasis. J. Clin. Invest. 91:1993;1390-1395.
27. Scott P., Natovitz P., Coffman R.L., Pearce E., Sher A. Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J. Exp. Med. 168:1988;675-679.
28. Sousa-Atta M.L.B., Salamé G.S., D'Olivera A., Almeida R.P., Atta A.M., Carvalho E.M. Immunoglobulin E anti-leishmanial antibody response in cutaneous leishmaniasis. Clin. Diagn. Lab. Immunol. 9:2002;101-104.
29. Vouldoukis I., Issaly F., Fourcade C., Paul-Eugene N., Arock M., Kolb J.P., Alves da Silva O., Monjour L., Poinsot H., Tselentis Y., Dugas B., Debré P., Mossalayi M.D. CD23 and IgE expression during human immune response to cutaneous leishmaniasis: possible role in monocyte activation. Res. Immunol. 145:1994;17-27.
30. Vouldoukis I., Riveros-Moreno V., Dugas B., Ouaaz F., Bécherel P., Debré P., Moncada S., Mossalayi D. The killing of Leishmania major by human macrophages is mediated by nitric oxide induced after ligation of the FcεRII/CD23 surface antigen. Proc. Nat. Acad. Sci. U.S.A. 92:1995;7804-7808.